ITUS Corporation (ITUS) Announces Positive Cchek Platform Data in Detecting Melanoma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall St rallies on bright earnings, megacaps' support
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
ITUS Demonstrates Efficacy of Its Cchek(TM) Early Cancer Detection Platform With Melanoma
September 28, 2016 9:03 AM EDTLOS ANGELES, CA -- (Marketwired) -- 09/28/16 -- ITUS Corporation ("ITUS") (NASDAQ: ITUS), today announced that it has successfully utilized its Cchek early cancer detection platform to identify the presence of Melanoma. Melanoma accounts for the vast majority of skin cancer deaths, which kills approximately 121,000 people per year worldwide.
Cchek is ITUS's early cancer detection technology, which measures a patient's immunological response to a malignancy by detecting the presence, absence, and quantity of certain unique... More
